Researchers developed and validated a pathomics signature based on 4 features to estimate prognosis and chemotherapy benefits in stage III colon cancer. The signature was found to be significantly associated with disease-free survival (DFS) and overall survival (OS) in training and validation cohorts. Patients with a low pathomics signature were more likely to benefit from chemotherapy, highlighting the potential of this signature in identifying patients who may benefit from treatment.
Journal Article by Jiang W, Wang H (…) Yan J et 8 al. in JAMA Surg